Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
3.520
-0.290 (-7.61%)
Nov 20, 2024, 4:00 PM EST - Market closed
Ironwood Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 378.42 | 442.74 | 410.6 | 413.75 | 389.52 | 428.41 | Upgrade
|
| Revenue Growth (YoY) | -12.48% | 7.83% | -0.76% | 6.22% | -9.08% | 23.59% | Upgrade
|
| Cost of Revenue | 125.41 | 104.79 | 44.27 | 70.41 | 91.2 | 135.39 | Upgrade
|
| Gross Profit | 253.01 | 337.95 | 366.33 | 343.35 | 298.33 | 293.02 | Upgrade
|
| Selling, General & Admin | 157.65 | 142.11 | 115.99 | 111.13 | 140 | 170.05 | Upgrade
|
| Operating Expenses | 157.65 | 142.11 | 115.99 | 111.13 | 140 | 170.05 | Upgrade
|
| Operating Income | 95.36 | 195.84 | 250.34 | 232.22 | 158.32 | 122.97 | Upgrade
|
| Interest Expense | -32.79 | -21.63 | -7.6 | -31.15 | -29.48 | -36.6 | Upgrade
|
| Interest & Investment Income | 4.88 | 18.97 | 9.5 | 0.73 | 1.5 | 2.86 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.25 | 0.02 | 0.18 | -1.18 | -6.11 | 3.54 | Upgrade
|
| EBT Excluding Unusual Items | 67.7 | 193.2 | 252.42 | 200.61 | 124.24 | 92.77 | Upgrade
|
| Merger & Restructuring Charges | 8.86 | -45.82 | - | 0.04 | -15.38 | -3.62 | Upgrade
|
| Legal Settlements | - | - | - | - | - | -2.4 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | -27.81 | Upgrade
|
| Pretax Income | 71.56 | -948.07 | 252.42 | 200.66 | 108.86 | 58.94 | Upgrade
|
| Income Tax Expense | 74.68 | 83.49 | 77.36 | -327.79 | 2.69 | - | Upgrade
|
| Earnings From Continuing Operations | -3.12 | -1,032 | 175.07 | 528.45 | 106.18 | 58.94 | Upgrade
|
| Earnings From Discontinued Operations | - | - | - | - | - | -37.44 | Upgrade
|
| Net Income to Company | -3.12 | -1,032 | 175.07 | 528.45 | 106.18 | 21.51 | Upgrade
|
| Minority Interest in Earnings | 0.66 | 29.32 | - | - | - | - | Upgrade
|
| Net Income | -2.46 | -1,002 | 175.07 | 528.45 | 106.18 | 21.51 | Upgrade
|
| Net Income to Common | -2.46 | -1,002 | 175.07 | 528.45 | 106.18 | 21.51 | Upgrade
|
| Net Income Growth | - | - | -66.87% | 397.71% | 393.73% | - | Upgrade
|
| Shares Outstanding (Basic) | 158 | 155 | 154 | 162 | 159 | 156 | Upgrade
|
| Shares Outstanding (Diluted) | 158 | 155 | 186 | 164 | 161 | 156 | Upgrade
|
| Shares Change (YoY) | 2.17% | -16.57% | 13.32% | 2.34% | 2.97% | 2.22% | Upgrade
|
| EPS (Basic) | -0.02 | -6.45 | 1.13 | 3.26 | 0.67 | 0.14 | Upgrade
|
| EPS (Diluted) | -0.02 | -6.45 | 0.96 | 3.21 | 0.66 | 0.14 | Upgrade
|
| EPS Growth | - | - | -69.98% | 386.36% | 378.84% | - | Upgrade
|
| Free Cash Flow | 123.82 | 183.15 | 273.63 | 261.63 | 166.99 | 3.54 | Upgrade
|
| Free Cash Flow Per Share | 0.78 | 1.18 | 1.47 | 1.59 | 1.04 | 0.02 | Upgrade
|
| Gross Margin | 66.86% | 76.33% | 89.22% | 82.98% | 76.59% | 68.40% | Upgrade
|
| Operating Margin | 25.20% | 44.23% | 60.97% | 56.12% | 40.65% | 28.70% | Upgrade
|
| Profit Margin | -0.65% | -226.37% | 42.64% | 127.72% | 27.26% | 5.02% | Upgrade
|
| Free Cash Flow Margin | 32.72% | 41.37% | 66.64% | 63.23% | 42.87% | 0.83% | Upgrade
|
| EBITDA | 97.4 | 197.41 | 251.76 | 233.74 | 160.69 | 128.55 | Upgrade
|
| EBITDA Margin | 25.74% | 44.59% | 61.31% | 56.49% | 41.25% | 30.01% | Upgrade
|
| D&A For EBITDA | 2.04 | 1.58 | 1.42 | 1.52 | 2.36 | 5.58 | Upgrade
|
| EBIT | 95.36 | 195.84 | 250.34 | 232.22 | 158.32 | 122.97 | Upgrade
|
| EBIT Margin | 25.20% | 44.23% | 60.97% | 56.12% | 40.65% | 28.70% | Upgrade
|
| Effective Tax Rate | 104.36% | - | 30.65% | - | 2.47% | - | Upgrade
|
| Revenue as Reported | 378.42 | 442.74 | 410.6 | 413.75 | 389.52 | 428.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.